✦ LIBER ✦

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

✍ Scribed by Mariangela Atteno; Rosario Peluso; Luisa Costa; Stefania Padula; Salvatore Iervolino; Francesco Caso; Alessandro Sanduzzi; Ennio Lubrano; Antonio Del Puente; Raffaele Scarpa

Publisher: Springer
Year: 2010
Tongue: English
Weight: 108 KB
Volume: 29
Category: Article
ISSN: 0770-3198
DOI: 10.1007/s10067-009-1340-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods